ObvioHealth has developed two new digital tools to enhance precision and lower the burden on patients/caregivers in paediatric clinical trials.
The paediatric GI instrument and paediatric cry capture instrument are intended to lower subjectivity and enhance compliance in such trials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Leveraging artificial intelligence (AI), the paediatric GI instrument guides caregivers by collecting high-quality, privacy-compliant photos of the stool of the infant.
The tool also enables real-world collection of gastrointestinal data at a time when the number of paediatric-onset inflammatory bowel disease and other common gastrointestinal ailments are rising.
The paediatric cry capture instrument aids in recording crying episodes and obtaining data such as crying duration, kind and/or sounds.
Caregivers and parents who are likely to overestimate the length of their kids’ cries, find it difficult to obtain precise data.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBoth these tools comprise an option to transfer the collected data – image or audio – to the specialist rater platform to carry out scoring, optimising the rater workflow and notifying them of variability in their scores.
Parallelly, ObvioHealth is using AI to annotate scores and training algorithms to further aid the raters.
Apart from these digital instruments for paediatric trials, the company is currently developing other new digital tools for usage in an upcoming trial.
ObvioHealth CEO Ivan Jarry said: “There is a penury of innovation in paediatric research, and it is hindering the industry’s ability to deliver meaningful trial outcomes.
“We’re deploying these digital tools to make clinical research easier for the sponsors, as well as for the caregivers and their children and to ultimately provide kids with better therapeutics.”
In January this year, the company introduced an Augmented ePRO for decentralised clinical trials.
